A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

drug protocol number
MK0431A XR-289
drug sponsor
MSD
drug study
SITAGLIPTIN/ METFORMIN XR
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Ongoing
drug phase